Doximity, Inc. (D2OC34)
Sao Paulo Exchange · Brazil · prices in BRL · close of 15 Oct 2026
Key indicators
| Last close | BRL 24.93 |
|---|---|
| 52-week range | 14.36 – 63.20 |
| Return, 1 month / 3 months | +11.4% / +32.4% |
| Return, 1 year / 3 years | −58.9% / – |
| Trend | Uptrend |
| RSI (14) | 75 |
| Volatility (1 year) | 89.8% |
| Worst drawdown (1 year) | -76.3% |
| Average daily value traded | 0.01M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Doximity is a digital platform built for medical professionals, based in the United States. Doctors and other clinicians use it to connect with colleagues, read medical news, find career opportunities and complete continuing education. Pharmaceutical and healthcare organisations pay to reach these verified members through advertising and recruiting services. The company earns most of its revenue from these commercial customers rather than from the clinicians who use the network.
Doximity, Inc. is represented on the Sao Paulo Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code D2OC34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Doximity, Inc. (D2OC34) trades on the Sao Paulo Exchange in Brazil. It last closed at BRL 24.93 on 15 October 2026.
Its price-based Market X-Ray is 35 out of 100 (a weak price profile), ranking 1,124 of 1,454 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 58.9% and over the last three months it rose 32.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Sao Paulo Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 45 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 10.3% | ||
| From 52-week high | -60.6% | ||
| Momentum | 58 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 32.4% | ||
| 6-month return | 23.4% | ||
| 12-month return, skipping the last month | -63.1% | ||
| Stability (higher is calmer) | 8 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 89.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -76.3% | ||
| Liquidity | 27 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M BRL | ||
| Zero-volume days | 56.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.8% |
|---|---|
| 1 month | +11.4% |
| 3 months | +32.4% |
| 6 months | +23.4% |
| 1 year | −58.9% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 22.64 / 22.60 |
|---|---|
| Golden / death cross (60 days) | Golden, 0 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.25 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Sao Paulo Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.